The majority of triple-negative breast cancer may correspond to basal-like carcinoma, but triple-negative breast cancer is not identical to basal-like carcinoma
- PMID: 19536621
- DOI: 10.1007/s00795-008-0428-5
The majority of triple-negative breast cancer may correspond to basal-like carcinoma, but triple-negative breast cancer is not identical to basal-like carcinoma
Abstract
Recently, the concept of basal-like carcinoma has been proposed. However, there are only a few reports about the relationship between triple-negative cancer and basal-like carcinoma. In this article, we report the study of the expression of basal cell markers in 11 triple-negative cancers. Eight tumors (4 metaplastic carcinomas, 2 invasive ductal carcinomas, 1 invasive papillary carcinoma, and 1 medullary carcinoma) were positive for more than three markers among cytokeratins 5, 14, and 17, and p63. Three tumors (2 invasive ductal carcinomas and 1 apocrine carcinoma) were completely negative for all markers. Among 8 tumors positive for basal markers, cytokeratins 5 and 17 were expressed in all 8 tumors, cytokeratin 14 in 6 tumors, and p63 in 7 tumors. Finally, we conclude that the majority of triple-negative cancer may correspond to basal-like carcinoma, but the two entities are not identical. The use of combination immunohistochemistry including cytokeratins 5, 14, and 17 and p63 may contribute to the detection of basal-like carcinoma.
Similar articles
-
Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer.Mod Pathol. 2006 May;19(5):617-21. doi: 10.1038/modpathol.3800570. Mod Pathol. 2006. PMID: 16528377
-
Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile.Mod Pathol. 2006 Nov;19(11):1506-11. doi: 10.1038/modpathol.3800678. Epub 2006 Aug 25. Mod Pathol. 2006. PMID: 16941011
-
Basal-like immunophenotype markers and prognosis in early breast cancer.Tumori. 2010 Nov-Dec;96(6):966-70. Tumori. 2010. PMID: 21388060
-
Triple negative breast carcinomas: similarities and differences with basal like carcinomas.Appl Immunohistochem Mol Morphol. 2009 Dec;17(6):483-94. doi: 10.1097/PAI.0b013e3181a725eb. Appl Immunohistochem Mol Morphol. 2009. PMID: 19620842 Review.
-
Triple-negative breast cancer: current state of the art.Tumori. 2010 Nov-Dec;96(6):875-88. Tumori. 2010. PMID: 21388048 Review.
Cited by
-
Proteomic profiling of lipid rafts in a human breast cancer model of tumorigenic progression.Clin Exp Metastasis. 2011 Aug;28(6):529-40. doi: 10.1007/s10585-011-9389-5. Epub 2011 May 1. Clin Exp Metastasis. 2011. PMID: 21533873 Free PMC article.
-
May metaplastic breast carcinomas be actually basal-like carcinoma? Further evidence study with its ultrastructure and survival analysis.Med Oncol. 2011 Mar;28(1):42-50. doi: 10.1007/s12032-009-9399-1. Epub 2009 Dec 30. Med Oncol. 2011. PMID: 20041316
-
PKIB expression strongly correlated with phosphorylated Akt expression in breast cancers and also with triple-negative breast cancer subtype.Med Mol Morphol. 2012 Dec;45(4):229-33. doi: 10.1007/s00795-011-0565-0. Epub 2012 Dec 7. Med Mol Morphol. 2012. PMID: 23224602
-
Triple-Negative Breast Cancer: Clinical and Histological Correlations.Breast Care (Basel). 2011;6(4):273-278. doi: 10.1159/000331643. Epub 2011 Aug 26. Breast Care (Basel). 2011. PMID: 22135625 Free PMC article.
-
Molecular basis for therapy resistance.Mol Oncol. 2010 Jun;4(3):284-300. doi: 10.1016/j.molonc.2010.04.005. Epub 2010 Apr 24. Mol Oncol. 2010. PMID: 20466604 Free PMC article. Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous